Format

Send to

Choose Destination
Hematol Oncol Clin North Am. 2010 Dec;24(6):1187-201. doi: 10.1016/j.hoc.2010.08.002.

Hemoglobin gene therapy for β-thalassemia.

Author information

1
Columbia University, New York, NY, USA. ab13@columbia.edu

Abstract

Allogeneic stem cell transplantation currently is the only curative option for severe β-thalassemia and sickle cell disease. Human globin gene therapy with autotransplantation of transduced human hematopoietic stem cells is an exciting alternative approach to a potential cure. One patient with thalassemia has recently been reported to have clinical benefit after lentiviral human β-globin gene therapy. He has not required blood transfusions for almost 2 years. Most of the patient's gene correction and new human β-globin gene expression is caused by the expansion of a single clone in which the corrective transgene is inserted into an Hmga2 gene.

PMID:
21075288
DOI:
10.1016/j.hoc.2010.08.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center